Explorer Study: an ambitious clinical trial

News & Event

Explorer Study: an ambitious clinical trial

Explorer: an ambitious study and a rigorous methodology to assess the efficacy of a dressing in the treatment of diabetic foot wounds.LOGO EXPLORER 

 Foot ulcers are one of the most common complications of diabetes. Worldwide 15% of diabetic patients will  suffer from a foot wound at least once in their lifetime(1). Urgo Medical hopes to demonstrate the efficacy of  UrgoStart® Contact compared to a neutral dressing in the local treatment of these wounds. UrgoStart® Contact is  a TLC-NOSF (Nano-Oligo-Saccharide Factor) dressing shown in previous studies to be capable of restoring the  biochemical balance of wounds and promoting healing. Explorer is a randomised, controlled, double-blind trial  versus a neutral dressing; it complies with both European and American methodologies. The trial is being  coordinated by Doctor Jacques Martini, from the Department of Endocrinology and Diabetology at Rangueil Hospital  in Toulouse. 68 investigator centres are involved in the trial in Europe; 238 patients will be monitored over  the course of a 20-week treatment period and a 12-week follow-up period. The primary endpoint observed is the  complete healing rate at the end of a 20-week treatment period.


(1) International Diabetes Federation – Diabetes Atlas – 2012 edition and WHO

Last update : June 9, 2015